Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Sunesis Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sunesis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sunesis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sunesis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sunesis Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Sunesis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sunesis Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sunesis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sunesis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sunesis Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sunesis Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Sunesis Pharmaceuticals, Inc. Snapshot 5 Sunesis Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Sunesis Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Sunesis Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 Sunesis Pharmaceuticals, Inc. - Pipeline Products Glance 12 Sunesis Pharmaceuticals, Inc. - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Sunesis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Sunesis Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Sunesis Pharmaceuticals, Inc. - Drug Profiles 15 vosaroxin 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Small Molecule to Inhibit PDK1 for Oncology 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 SNS-062 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Sunesis Pharmaceuticals, Inc. - Pipeline Analysis 19 Sunesis Pharmaceuticals, Inc. - Pipeline Products by Target 19 Sunesis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 20 Sunesis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 21 Sunesis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 22 Sunesis Pharmaceuticals, Inc. - Recent Pipeline Updates 23 Sunesis Pharmaceuticals, Inc. - Dormant Projects 28 Sunesis Pharmaceuticals, Inc. - Discontinued Pipeline Products 29 Discontinued Pipeline Product Profiles 29 SNS-032 29 Sunesis Pharmaceuticals, Inc. - Company Statement 30 Sunesis Pharmaceuticals, Inc. - Locations And Subsidiaries 32 Head Office 32 Other Locations & Subsidiaries 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables Sunesis Pharmaceuticals, Inc., Key Information 5 Sunesis Pharmaceuticals, Inc., Key Facts 5 Sunesis Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7 Sunesis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8 Sunesis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9 Sunesis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 10 Sunesis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 Sunesis Pharmaceuticals, Inc. - Phase III, 2014 12 Sunesis Pharmaceuticals, Inc. - Phase II, 2014 13 Sunesis Pharmaceuticals, Inc. - Preclinical, 2014 14 Sunesis Pharmaceuticals, Inc. - Pipeline by Target, 2014 19 Sunesis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 20 Sunesis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 21 Sunesis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 22 Sunesis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 23 Sunesis Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 28 Sunesis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 29 Sunesis Pharmaceuticals, Inc., Subsidiaries 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.